CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $154.77M, lower than 95% of all stocks globally
- PositionPrice-to-book is 13.18×, higher than 95% of its Biotechnology peers (median 2.86×)
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
220.58BKRW154.77M · vs all stocks (USD)
Revenue (TTM)
16.48BKRW11.57M · vs all stocks (USD)
Profit Margin
-49.87%vs Biotechnology peers
Beta
1.34xvs all stocks
52-Week Change
-11.83%vs all stocks
Market Capitalization
220.58BKRW154.77M · vs all stocks (USD)
Enterprise Value
259.16BKRW181.84M · vs all stocks (USD)
Price to Sales (TTM)
13.90xvs Biotechnology peers
Price to Book (MRQ)
13.18xvs Biotechnology peers
Enterprise to Revenue
15.72xvs Biotechnology peers
Enterprise to EBITDA
-35.09xvs Biotechnology peers
Gross Margin
54.09%vs Biotechnology peers
Profit Margin
-49.87%vs Biotechnology peers
Operating Margin
-68.04%vs Biotechnology peers
Return on Assets (TTM)
-14.73%vs Biotechnology peers
Return on Equity (TTM)
-41.23%vs Biotechnology peers
Revenue (TTM)
16.48BKRW11.57M · vs all stocks (USD)
Revenue per Share (TTM)
1.37KKRWUpdated Jul 14, 2026Quarterly Revenue Growth
-1.40%vs Biotechnology peers
Gross Profit (TTM)
7.71BKRW5.41M · vs all stocks (USD)
EBITDA (TTM)
-7.39BKRW-5.18M · vs all stocks (USD)
Net Income (TTM)
-8.22BKRW-5.77M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-1.45%vs Biotechnology peers
Operating Cash Flow (TTM)
-7.26BKRW-5.10M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-10.21BKRW-7.16M · vs all stocks (USD)
Payout Ratio
0.00%vs Biotechnology peers
Minority Interest (Equity)
8.05BKRWFY2025 · Dec 31, 2025Revenue
16.55BKRWFY2025 · Dec 31, 2025Cost of Goods Sold
9.00BKRWFY2025 · Dec 31, 2025Gross Profit
7.55BKRWFY2025 · Dec 31, 2025Operating Income
-8.34BKRW-5.85M · vs all stocks (USD)
Pre-tax Income
-6.81BKRWFY2025 · Dec 31, 2025Income Tax Expense
250.51MKRWFY2025 · Dec 31, 2025Net Income
-7.06BKRWFY2025 · Dec 31, 2025EBIT
-5.36BKRWFY2025 · Dec 31, 2025EBITDA (Income Statement)
-5.89BKRWFY2025 · Dec 31, 2025Research & Development
9.18BKRWFY2025 · Dec 31, 2025Selling, General & Administrative
2.69BKRWFY2025 · Dec 31, 2025Other Operating Expenses
272.84MKRWFY2025 · Dec 31, 2025Non-operating Interest Income
369.52MKRWFY2025 · Dec 31, 2025Non-operating Interest Expense
1.45BKRWFY2025 · Dec 31, 2025EPS (Basic)
-684.00KRWFY2025 · Dec 31, 2025EPS (Diluted)
-684.00KRWFY2025 · Dec 31, 2025Basic Shares Outstanding
11.87MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
11.87MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-6.81BKRWFY2025 · Dec 31, 2025Minority Interests (P&L)
-1.06BKRWFY2025 · Dec 31, 2025Operating Cash Flow
-4.17BKRWFY2025 · Dec 31, 2025Free Cash Flow
-8.54BKRWFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
6.09BKRWFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-6.81BKRWFY2025 · Dec 31, 2025Stock-based Compensation
442.35MKRWFY2025 · Dec 31, 2025Other Non-cash Items
1.01BKRWFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-155.49MKRWFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
1.33BKRWFY2025 · Dec 31, 2025Capital Expenditures
-4.37BKRWFY2025 · Dec 31, 2025Net Intangibles (CF)
-15.00MKRWFY2025 · Dec 31, 2025Purchase of Investments
-11.61BKRWFY2025 · Dec 31, 2025Sale of Investments
22.19BKRWFY2025 · Dec 31, 2025Other Investing Activity
-563.05MKRWFY2025 · Dec 31, 2025Net Investing Cash Flow
5.65BKRWFY2025 · Dec 31, 2025Long-term Debt Issuance
6.30BKRWFY2025 · Dec 31, 2025Long-term Debt Payments
-6.66BKRWFY2025 · Dec 31, 2025Other Financing Charges
-20.00KRWFY2025 · Dec 31, 2025Net Financing Cash Flow
1.29BKRWFY2025 · Dec 31, 2025Shares Outstanding
12.39MSharesUpdated Jul 14, 2026Float Shares
9.11MSharesUpdated Jul 14, 2026% Held by Insiders
22.76%vs all stocks
% Held by Institutions
0.60%vs all stocks
Total Cash (MRQ)
11.14BKRW7.81M · vs all stocks (USD)
Total Cash per Share (MRQ)
900.20KRWUpdated Jul 14, 2026Total Debt (MRQ)
13.15BKRW9.23M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.7867xvs Biotechnology peers
Current Ratio (MRQ)
1.87xvs Biotechnology peers
Book Value per Share (MRQ)
1.35KKRWUpdated Jul 14, 2026Total Assets
41.22BKRW28.92M · vs all stocks (USD)
Total Current Assets
19.83BKRWFY2025 · Dec 31, 2025Total Liabilities
24.49BKRWFY2025 · Dec 31, 2025Total Non-current Assets
21.39BKRWFY2025 · Dec 31, 2025Total Non-current Liabilities
12.17BKRWFY2025 · Dec 31, 2025Total Current Liabilities
12.32BKRWFY2025 · Dec 31, 2025Cash Equivalents
6.09BKRWFY2025 · Dec 31, 2025Cash & Cash Equivalents
6.09BKRWFY2025 · Dec 31, 2025Other Short-term Investments
8.58BKRWFY2025 · Dec 31, 2025Accounts Receivable
1.61BKRWFY2025 · Dec 31, 2025Inventory
1.90BKRWFY2025 · Dec 31, 2025Accounts Payable
376.97MKRWFY2025 · Dec 31, 2025Short-term Debt
5.09BKRWFY2025 · Dec 31, 2025Other Current Liabilities
1.21KKRWFY2025 · Dec 31, 2025Long-term Debt
7.11BKRWFY2025 · Dec 31, 2025Other Non-current Liabilities
-1.11KKRWFY2025 · Dec 31, 2025Common Stock (Book)
6.11BKRWFY2025 · Dec 31, 2025Retained Earnings
-82.95BKRWFY2025 · Dec 31, 2025Total Shareholders' Equity
16.73BKRW11.74M · vs all stocks (USD)
52-Week Low
17.10KKRWUpdated Jul 14, 202652-Week High
42.60KKRWUpdated Jul 14, 202652-Week Change
-11.83%vs all stocks
Beta
1.34xvs all stocks
50-Day MA
27.50KKRWUpdated Jul 14, 2026200-Day MA
29.88KKRWUpdated Jul 14, 2026Avg 10-Day Volume
44.36KSharesUpdated Jul 14, 2026Avg 30-Day Volume
83.68KSharesUpdated Jul 14, 2026Diluted EPS (TTM)
-684.00KRWUpdated Jul 14, 20262 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsWhere is this company structurally exposed?
Ulcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
It sits well below its peak, and the fall has been both deep and long.
Partial Recovery After Sharp Decline
A weak, thin-volume bounce inside a decline that is still far from recovered.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Price-to-book is 13.18×, higher than 95% of its Biotechnology peers (median 2.86×)Significant
Price-to-book: 13.18Industry median: 2.86Industry P95: 13.08Peers compared: 260
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.54Profit Margin: -0.50
Financial Health
Altman Z-Score 2.78: safe zoneNotable
Altman Z-Score: 2.78
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $154.77M, lower than 95% of all stocks globallySignificant
Market cap (USD): 154,771,552.131Global P5: 275,556,405.438
Revenue is $11.57M, lower than 95% of all stocks globallySignificant
Revenue (USD): 11,565,505.833Global P5: 33,357,653.812
Companies that share the same coordination system — how they create, deliver, or capture value.
Chill Brands Group Plc
Tier 1ProductionApproval-Gated PipelineRuleFlow
EKF Diagnostics Holdings plc
Tier 1ProductionApproval-Gated PipelineRuleFlow
HLB Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Yungjin Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Graphy Inc.
Tier 1ProductionApproval-Gated PipelineRule
Enlivex Therapeutics Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Sensorion SA
Tier 1ProductionApproval-Gated PipelineRuleRisk
Cellectis S.A.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Mycenax Biotech Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Journey Medical Corp
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Hengsheng Energy Co., Ltd.
2 interpretationsUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedPartial Recovery After Sharp Decline
Enlivex Therapeutics Ltd.
2 interpretationsUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedPartial Recovery After Sharp Decline
Catenai plc
2 interpretationsUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedPartial Recovery After Sharp Decline